These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 6490416)

  • 41. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia.
    Johansson PA; Andersson M; Andersson KE; Cenci MA
    Neurobiol Dis; 2001 Apr; 8(2):220-39. PubMed ID: 11300719
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
    McPherson RJ; Marshall JF
    Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential modulation of dopamine D1-receptor binding and mRNA expression in the basal ganglia by the D1-receptor antagonist, SCH-23390.
    Yu J; Coirini H; Källström L; Wiesel FA; Johnson AE
    Synapse; 1998 Sep; 30(1):38-48. PubMed ID: 9704879
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Thioridazine 5-sulfoxide diastereoisomers in serum and urine from rats and man after chronic thioridazine administration.
    Hale PW; Poklis A
    J Anal Toxicol; 1985; 9(5):197-201. PubMed ID: 4057956
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stereoselective analysis of thioridazine-2-sulfoxide and thioridazine-5-sulfoxide: an investigation of rac-thioridazine biotransformation by some endophytic fungi.
    Borges KB; De Souza Borges W; Pupo MT; Bonato PS
    J Pharm Biomed Anal; 2008 Apr; 46(5):945-52. PubMed ID: 17614234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The assay of plasma concentration of thioridazine and its metabolites as a function of time.
    Gottschalk LA; Dinovo EC; Nandi BR
    Commun Psychopharmacol; 1978; 2(6):475-9. PubMed ID: 747914
    [No Abstract]   [Full Text] [Related]  

  • 47. Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia.
    Andersson M; Terasmaa A; Fuxe K; Strömberg I
    J Neurosci Res; 2005 Oct; 82(2):264-72. PubMed ID: 16175569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Down-regulation of dopamine D1 and D2 receptors in the basal ganglia of PTZ kindling model of epilepsy: effects of angiotensin IV.
    Tchekalarova J; Sotiriou E; Angelatou F
    Brain Res; 2004 Oct; 1024(1-2):159-66. PubMed ID: 15451378
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Peculiarities of L: -DOPA treatment of Parkinson's disease.
    Kostrzewa RM; Nowak P; Kostrzewa JP; Kostrzewa RA; Brus R
    Amino Acids; 2005 Mar; 28(2):157-64. PubMed ID: 15750845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Thioridazine-fluoxetine interaction at the level of the distribution process in vivo.
    Wójcikowski J; Daniel WA
    Pol J Pharmacol; 2002; 54(6):647-54. PubMed ID: 12866720
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors.
    Kent TA; Wilber RD
    J Nerv Ment Dis; 1982 Aug; 170(8):502-4. PubMed ID: 7097268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of surgery targeting the caudal intralaminar thalamic nuclei on the pathophysiological functioning of basal ganglia in a rat model of Parkinson's disease.
    Kerkerian-Le Goff L; Bacci JJ; Jouve L; Melon C; Salin P
    Brain Res Bull; 2009 Feb; 78(2-3):80-4. PubMed ID: 18790021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Changes in cerebral dopamine function induced by a year's administration of trifluoperazine or thioridazine and their subsequent withdrawal.
    Clow A; Theodorou A; Jenner P; Marsden CD
    Adv Biochem Psychopharmacol; 1980; 24():335-40. PubMed ID: 7190762
    [No Abstract]   [Full Text] [Related]  

  • 54. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R; Greenamyre JT
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Motor effects of buspirone: Relationship with dopamine and serotonin in the striatum.
    Shireen E; Haleem DJ
    J Coll Physicians Surg Pak; 2005 Dec; 15(12):753-6. PubMed ID: 16398963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dopamine receptors in the basal ganglia: relevance to Parkinson's disease.
    Strange PG
    Mov Disord; 1993 Jul; 8(3):263-70. PubMed ID: 8101967
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Mesoridazine (Lidanor"Sandoz")--a new neuroleptic closely related to thioridazine].
    Lingjaerde O
    Tidsskr Nor Laegeforen; 1975 Mar; 95(7):450-1. PubMed ID: 1129743
    [No Abstract]   [Full Text] [Related]  

  • 58. Plasma level monitoring of antipsychotic drugs. Clinical utility.
    Dahl SG
    Clin Pharmacokinet; 1986; 11(1):36-61. PubMed ID: 2868820
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thioridazine pharmacodynamics: clinical effects may depend upon drug metabolism.
    Lewis MH; Mobilio JN; Rissmiller DJ; Mailman RB
    J Am Osteopath Assoc; 1984 Sep; 84(1 Suppl):124-8. PubMed ID: 6490416
    [No Abstract]   [Full Text] [Related]  

  • 60. Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.
    Niedzwiecki DM; Mailman RB; Cubeddu LX
    J Pharmacol Exp Ther; 1984 Mar; 228(3):636-9. PubMed ID: 6707914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.